IPP Bureau
AstraZeneca delivers double-digit growth
By IPP Bureau - November 10, 2025
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
SOUKYA launches Rs. 125 crore, 100-bed AYUSH hospital in Bengaluru
By IPP Bureau - November 10, 2025
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Johnson & Johnson gets FDA nod for new depression treatment
By IPP Bureau - November 10, 2025
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
By IPP Bureau - November 10, 2025
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies
By IPP Bureau - November 10, 2025
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Bristol Myers Squibb prices €5 billion senior unsecured notes offering
By IPP Bureau - November 10, 2025
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
By IPP Bureau - November 10, 2025
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
By IPP Bureau - November 10, 2025
Venus Remedies now has 29 active product approvals in Vietnam alone
Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
By IPP Bureau - November 10, 2025
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Novo Nordisk India partners with Emcure to commercialise Poviztra in India
By IPP Bureau - November 10, 2025
Poviztra is a second brand of Wegovy
Glenmark secures China approval for Ryaltris
By IPP Bureau - November 10, 2025
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Marksans Pharma's Goa unit clears FDA inspection
By IPP Bureau - November 10, 2025
The said inspection concluded with Zero Form 483 observation
Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr
By IPP Bureau - November 09, 2025
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
By IPP Bureau - November 09, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr
By IPP Bureau - November 09, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
